Revolution Medicines Plans Solo European Drug Launch
Revolution Medicines is preparing a broad European commercial rollout for its pancreatic cancer drug. Backed by funding and recent hires, the company aims to bypass local partners.
Insights:
Revolution Medicines is preparing a solo European rollout for its pancreatic cancer drug, aiming to bypass local licensing partners. Analysts forecast peak global sales of $11.5 billion for the therapy following an expedited FDA approval in the United States. The move reflects growing confidence among mid-sized drug developers to manage international commercialization independently.
